Y Rostom1, H Zaghloul, G Khedr, W El-Shazly, D Abd-Allah. 1. Clinical Oncology Department, Faculty of Medicine, Alexandria University, Champlion Street, Alazarita, Alexandria 21131, Egypt.
Abstract
PURPOSE: This study was conducted to evaluate the feasibility, efficacy, and toxicities of docetaxel-based induction chemotherapy and chemoradiotherapy in patients with localized gastric or gastroesophageal adenocarcinoma. METHODS:Patients with localized, operable gastric or gastroesophageal adenocarcinoma received two cycles of induction chemotherapy of fluorouracil, docetaxel, and cisplatin (TPF) followed by 45 Gy of radiation and concurrent fluorouracil plus docetaxel then surgery for nonmetastatic patients. RESULTS:Forty-one patients were included. Pretreatment T3 was encountered in 56 % of patients while 61 % had N1 disease. A pathologic complete response (CR) was noted in 24 % of patients. Pathologic response was significantly associated with baseline T stage (P < 0.001) and N stage (P = 0.002). The 3-year overall survival (OS) and disease-free survival were 47.3 and 42.1 %, respectively. OS was significantly correlated with R0 resection (P = 0.027), pathological response (P = 0.01), dissected pathologically positive lymph node (P = 0.037), and postsurgery (T) stage (P = 0.02). Toxicities were manageable and there were no treatment-related deaths. CONCLUSION:Docetaxel-based chemoradiotherapy in localized gastric adenocarcinoma patients resulted in 24 % path CR and was not associated with a higher percentage of postoperative complications. A well-designed randomized controlled trial is mandatory to further endorse this evolving approach.
RCT Entities:
PURPOSE: This study was conducted to evaluate the feasibility, efficacy, and toxicities of docetaxel-based induction chemotherapy and chemoradiotherapy in patients with localized gastric or gastroesophageal adenocarcinoma. METHODS:Patients with localized, operable gastric or gastroesophageal adenocarcinoma received two cycles of induction chemotherapy of fluorouracil, docetaxel, and cisplatin (TPF) followed by 45 Gy of radiation and concurrent fluorouracil plus docetaxel then surgery for nonmetastatic patients. RESULTS: Forty-one patients were included. Pretreatment T3 was encountered in 56 % of patients while 61 % had N1 disease. A pathologic complete response (CR) was noted in 24 % of patients. Pathologic response was significantly associated with baseline T stage (P < 0.001) and N stage (P = 0.002). The 3-year overall survival (OS) and disease-free survival were 47.3 and 42.1 %, respectively. OS was significantly correlated with R0 resection (P = 0.027), pathological response (P = 0.01), dissected pathologically positive lymph node (P = 0.037), and postsurgery (T) stage (P = 0.02). Toxicities were manageable and there were no treatment-related deaths. CONCLUSION:Docetaxel-based chemoradiotherapy in localized gastric adenocarcinomapatients resulted in 24 % path CR and was not associated with a higher percentage of postoperative complications. A well-designed randomized controlled trial is mandatory to further endorse this evolving approach.
Authors: Jaffer A Ajani; Miguel B Fodor; Sergei A Tjulandin; Vladimir M Moiseyenko; Yee Chao; Sebastiao Cabral Filho; Alejandro Majlis; Sylvie Assadourian; Eric Van Cutsem Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Se Hoon Park; Won Ki Kang; Hyo Rak Lee; Jinny Park; Kyung-Eun Lee; Se Hoon Lee; Joon Oh Park; Kihyun Kim; Won Seog Kim; Chul Won Chung; Young-Hyuk Im; Mark H Lee; Chan H Park; Keunchil Park Journal: Am J Clin Oncol Date: 2004-10 Impact factor: 2.339
Authors: Peter C Thuss-Patience; Albrecht Kretzschmar; Michael Repp; Dorothea Kingreen; Dirk Hennesser; Simone Micheel; Daniel Pink; Christian Scholz; Bernd Dörken; Peter Reichardt Journal: J Clin Oncol Date: 2005-01-20 Impact factor: 44.544
Authors: I Songun; H J Keizer; J Hermans; P Klementschitsch; J E de Vries; J A Wils; J van der Bijl; J H van Krieken; C J van de Velde Journal: Eur J Cancer Date: 1999-04 Impact factor: 9.162
Authors: J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus Journal: N Engl J Med Date: 1999-03-25 Impact factor: 91.245
Authors: J A Ajani; P F Mansfield; P M Lynch; P W Pisters; B Feig; P Dumas; D B Evans; I Raijman; K Hargraves; S Curley; D M Ota Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: Víctor Valentí; José Luis Hernández-Lizoain; Fernando Martínez Regueira; Aurora Gil; Pablo Martí; Gabriel Zozaya; Alvaro Bueno; Nicolás Pedano; Jorge Arredondo; M Carmen Beorlegui; Javier Alvarez-Cienfuegos Journal: Cir Esp Date: 2009-10-31 Impact factor: 1.653
Authors: Milan Vošmik; Jan Laco; Igor Sirák; Josef Dvořák; Petr Lochman; Miroslav Hodek; Petra Malá; Stanislav Rejchrt; Rudolf Repák; Michal Leško; Alexander Ferko; Aleš Ryška; Bohuslav Melichar; Jiří Petera Journal: Pathol Oncol Res Date: 2017-05-27 Impact factor: 3.201